Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Longitudinal PET Study of Tau Tracer 18F-PI-2620 in Individuals With Down Syndrome
2024-515574-27-00Phase 2Authorised
- Sponsor
- Hospital de la Santa Creu i Sant Pau Research Institute
- Start
- Jul 2024
- Modality
- Antibody-Radionuclide Conjugates → Antibody Conjugates → Antibody-Based Therapeutics, Positron Emitters → Radiopharmaceuticals, Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label trial of 18F-PI-2620 in Down syndrome and Alzheimer's disease (AD) (2 cohorts), sponsored by Hospital de la Santa Creu i Sant Pau Research Institute. Primary endpoints: Brain tau SUVR with 18F-PI-2620 and Adverse events within 24 hours of tracer administration. Planned start Jul 2024; status: authorised.
02
Drugs
18F-PI-2620
03
Conditions
Down syndromeAlzheimer's disease (AD)
Beyond the preview
Go deeper on 2024-515574-27-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2024-515574-27-00.